文献速递妇科生殖医学

以血清抗苗勒管激素替代多囊卵巢形态学增加多囊卵巢综合征诊断人数:一项基于社区的横断面研究

Substituting serum anti-Müllerian hormone for polycystic ovary morphology increases the number of women diagnosed with polycystic ovary syndrome: a community-based cross-sectional study.
PubMed 文献 · Hum Reprod · 2021-01-01

这项澳大利亚社区横断面研究纳入163名非因医疗问题就诊的女性,比较血清抗苗勒管激素(AMH)替代超声多囊卵巢形态(PCOM)作为多囊卵巢综合征(PCOS)诊断标准的影响。两种AMH检测(Ansh和BA2)均与PCOM有良好相关性,但替代后约5%参与者PCOS分类发生改变,总体使诊断人数增加。

要点

  • 血清AMH与PCOM相关性好,但替代PCOM会使约5%参与者PCOS分类改变。
  • Ansh检测AMH≥44.0 pmol/l识别PCOM灵敏度80.6%、假阳性率15.2%、阳性预测值55.6%。
  • BA2检测AMH≥33.2 pmol/l识别PCOM灵敏度80.6%、特异度79.5%、阳性预测值48.1%。

核心结论

  • 尽管血清AMH与PCOM相关性好,以高血清AMH替代PCOM作为PCOS诊断标准导致5%参与者PCOS分类改变,主要效应是更多女性被诊断为PCOS,但部分既往诊断为PCOS者不再符合诊断。

研究设计与样本

  • 澳大利亚社区横断面研究,纳入163名非因医疗问题就诊的女性,平均(标准差)年龄32.5(5.5)岁。
  • 血清AMH同时用Ansh picoAMH和Beckman Coulter Access 2(BA2)两种检测法测定,雄激素用液相色谱-串联质谱法测定,并行高分辨率卵巢超声。
  • PCOS按鹿特丹标准判定,PCOM按雄激素过多-PCOS工作组建议定义为至少一侧卵巢≥25个卵泡。
  • 通过受试者工作特征(ROC)曲线确定最佳识别PCOM的血清AMH截断值。

主要发现

  • 孤立性PCOM女性Ansh AMH中位数(范围)为56.9 pmol/l(34.6, 104.2),无PCOS特征女性为18.7(3.2, 50.9),P=0.002。
  • 孤立性PCOM女性BA2 AMH中位数(范围)为38.5 pmol/l(22.2, 100.2),无PCOS特征女性为16.7(3.5, 38.9),P=0.002。
  • Ansh检测AMH≥44.0 pmol/l识别PCOM的灵敏度为80.6%,假阳性率15.2%,阳性预测值55.6%,阴性预测值94.9%。
  • BA2检测AMH≥33.2 pmol/l识别PCOM的灵敏度为80.6%,特异度79.5%,阳性预测值48.1%,阴性预测值94.6%。
  • 以血清AMH替代PCOM作为PCOS诊断标准时,Ansh检测使7名女性新增诊断为PCOS、1名不再诊断为PCOS;BA2检测使8名新增、2名不再诊断;两种检测合计使6名女性新增诊断为PCOS。

关键数值与推荐

  • PCOS诊断采用鹿特丹标准,PCOM定义为至少一侧卵巢≥25个卵泡(雄激素过多-PCOS工作组建议)。
  • Ansh检测血清AMH≥44.0 pmol/l为识别PCOM的ROC曲线建议截断值。
  • BA2检测血清AMH≥33.2 pmol/l为识别PCOM的截断值。

临床怎么用

  • 血清AMH绝对值因检测方法而异,需针对每种检测建立特定参考范围。
  • 在社区样本中以血清AMH替代PCOM诊断PCOS会改变PCOS分类人数,总体风险增加但部分女性不再被归类为PCOS。

局限性

  • 未排除功能性低促性腺激素性性腺功能减退症女性,可能被误分类为稀发/无排卵-PCOM表型。
  • 研究参与者主要为白人/白种人, findings不能推广至其他种族女性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

STUDY QUESTION: Can serum anti-Müllerian hormone (AMH) replace polycystic ovary morphology (PCOM) determined by ultrasound as a diagnostic component of polycystic ovary syndrome (PCOS)? SUMMARY ANSWER: Despite good correlations between serum AMH and PCOM, the use of a high serum AMH as a proxy for PCOM resulted in the reclassification of PCOS in 5% of study participants, with the main effect being more women identified, although some women previously classified as having PCOS were no longer classified as such. WHAT IS KNOWN ALREADY: AMH has been proposed as an alternative to PCOM as a diagnostic component of PCOS. Previous studies are limited by poorly defining PCOS, use of infertile women as comparators, measurement of hormones by immunoassay that lack precision in the female range, low-resolution ovarian ultrasound and inconsistent handling and storage of serum samples. STUDY DESIGN, SIZE, DURATION: This is an Australian cross-sectional study of 163 non-healthcare-seeking women. PARTICIPANTS/MATERIALS, SETTING, METHODS: Serum AMH was measured by both the Ansh picoAMH assay and the Beckman Coulter Access 2 (BA2) assay, in parallel with androgens measured by liquid chromatography-tandem mass spectrometry, in blood samples of women, not pregnant, breast feeding or using systemic steroids, who also underwent high-resolution ovarian ultrasound. PCOS was determined by the Rotterdam criteria with PCOM defined by the Androgen Excess-PCOS Taskforce recommendation of ≥25 follicles in at least one ovary. Cut-off serum concentrations that best identified women as having PCOM were identified by receiver operator characteristic (ROC) curves. MAIN RESULTS AND THE ROLE OF CHANCE: A total of 163 women, mean (SD) age 32.5 (5.5) years, who provided a blood sample and had both ovaries visualized on ultrasound were included in the analysis. Women with isolated PCOM had higher median (range) Ansh AMH and BA2 AMH concentrations than those with no PCOS characteristics [56.9 pmol/l (34.6, 104.2) versus 18.7 (3.2, 50.9), P = 0.002 and 38.5 pmol/l (22.2, 100.2) versus 16.7 (3.5, 38.9), P = 0.002, respectively]. An AMH ≥ 44.0 pmol/l, suggested by the ROC curve, identified 80.6% of women with PCOM, falsely identified 15.2% of women without PCOM as having PCOS and had a positive predictive value of 55.6%. The negative predictive value was 94.9%. An AMH BA2 assay cut-off of ≥33.2 pmol/l provided a sensitivity of 80.6%, a specificity of 79.5% and a positive predictive value for PCOM of 48.1%. The negative predictive value was 94.6% for PCOM. When serum AMH was used in the place of PCOM as a diagnostic criterion for PCOS, the Ansh assay resulted in an additional seven women classified as having PCOS and no longer classified one woman as having PCOS. For the BA2 assay, eight additional and two fewer women were classified as having PCOS. Overall, both assays resulted in six more women being classified as having PCOS. LIMITATIONS, REASONS FOR CAUTION: Women with functional hypogonadotrophic hypogonadism were not excluded and may have been misclassified as having an oligo-amenorrhoea-PCOM phenotype. As study participants were predominantly Caucasian/White, our findings cannot be generalized to women of other ethnicities. WIDER IMPLICATIONS OF THE FINDINGS: Although serum AMH reflects the number of developing ovarian follicles, the absolute values vary between assays and specific reference ranges for individual assays are required. Irrespective of the assay used, replacing PCOM with serum AMH to diagnose PCOS in a community-based sample altered the number of women classified as having or not having PCOS. Consequently, although overall the risk of women being identified as having PCOS would be increased, some women would no longer be classified as having this condition. STUDY FUNDING/COMPETING INTEREST(S): The study was supported by the Norman Beischer Research Foundation and the Grollo-Ruzzene Foundation. S.R.D. is an NHMRC Senior Principal Research Fellow (Grant No. 1135843). S.R.D. reports unrelated support that includes grants from the NHMRC Australia, personal fees for educational activities from Besins Healthcare, Abbott Chile, BioFemme and Pfizer Australia, personal Advisory Board/consultancy fees from Theramex, Abbott Laboratories, Astellas, Mayne Pharmaceuticals, Roche Diagnostics, Lawley Pharmaceuticals and Que Oncology and has received institutional grant funding from Que Oncology and Ovoca research. The other authors declare no conflicts of interest. TRIAL REGISTRATION NUMBER: N/A.

来源:Hum Reprod,查看原文。版权归原作者所有。

引用

  1. Bell RJ, Islam RM, Skiba MA, et al. Substituting serum anti-Müllerian hormone for polycystic ovary morphology increases the number of women diagnosed with polycystic ovary syndrome: a community-based cross-sectional study. Hum Reprod. 2021. PMID: 34741176. doi:10.1093/humrep/deab232

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。